Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is up huge after the company announced an commendation with the bureau on a Special Protocol Assessment for its Phase 3 Trial of KRX-0401 in the treatment of multiple myeloma. KERX is up almost 50% from this morning’s programme and we hit seen almost 9.9 million shares change hands as of 10:38 AM ESt. This trades an cipher of about 2.2 million shares and its 52-week arrange is $0.09 to $1.88.
This programme also has partner Aeterna Zentaris Inc. (NASDAQ: AEZS) trading up nearly 7% at $2.80 on 490,000 shares. Its 52-week arrange is $0.26 to $3.25 and cipher intensity is 235,000 shares.
Jon C. Ogg
August 3, 2009 (10:38 AM EST)
No comments:
Post a Comment